Arcutis submits sNDA for roflumilast with US FDA to treat scalp and body psoriasis
Arcutis Biotherapeutics, Inc, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, has announced the submission of a supplemental New Drug Application (sNDA) for Zoryve (roflumilast) foam 0.3%, a …